A new review lays out a pragmatic framework for managing diabetes mellitus (DM) across the full spectrum of cirrhosis, highlighting where standard diabetes playbooks fall short and where frontline clinicians can spot it early to reduce morbidity, mortality, and medication-related harm. The paper emphasizes that metformin remains the backbone in compensated cirrhosis, while insulin is the cornerstone in decompensated disease and during hospitalization, with HbA1c often unreliable in advanced liver disease.

Why It Matters To Your Practice

• NPs and PAs are often the first to spot the cirrhosis-plus-DM collision: worsening glucose control, sarcopenia, ascites, edema, hypoglycemia risk, and shifting medication tolerance.

• As MASLD rises globally, diabetes is becoming a major upstream driver of liver injury — but DM also shows up in non-metabolic cirrhosis, including viral hepatitis.

• Routine diabetes algorithms can miss the mark in cirrhosis, especially when HbA1c underestimates or misrepresents glycemia in advanced liver disease.

• This review argues for stage-specific, liver-safe management rather than treating these patients like standard type 2 diabetes cases.

Clinical Benefits

• In compensated cirrhosis, metformin remains first-line when appropriate, offering a familiar foundation for outpatient management.

• GLP-1 receptor agonists and SGLT2 inhibitors show promise in compensated disease, especially for patients with MASLD and cardio-renal comorbidities.

• When HbA1c is unreliable, oral glucose tolerance testing and continuous glucose monitoring can improve diagnostic accuracy and day-to-day treatment decisions.

• Frequent reassessment, nutrition optimization, and coordinated hepatology-endocrinology care can help you tailor goals to the patient in front of you — exactly where experienced NPs and PAs shine.

Managing Risks

• Use caution with sulfonylureas, insulin secretagogues, and drugs linked to fluid retention as hepatic reserve declines.

• In decompensated cirrhosis and inpatient care, insulin becomes the cornerstone — but conservative dosing and dynamic titration are essential to avoid hypoglycemia.

• Do not rely blindly on rigid glycemic targets; liver disease severity, nutrition status, renal function, and hospitalization all change the risk-benefit balance.

• Watch for hepatogenous diabetes and cirrhosis-related glucose dysregulation, which may not behave like classic type 2 DM.

The Bottom Line

• Cirrhosis plus DM is not “routine diabetes care with extra steps” — it is a higher-risk, stage-dependent management challenge.

• Your frontline assessment matters: the right NP/PA can spot decompensation, question a misleading HbA1c, and adjust therapy before complications snowball.

• Best practice is individualized: prioritize hepatic safety, metabolic stability, and practical follow-up over one-size-fits-all glucose control.

• Bottom line: in compensated cirrhosis, think metformin-first and selective newer agents; in decompensated cirrhosis or hospitalization, think insulin-first and titrate carefully.